Please login to the form below

Not currently logged in
Email:
Password:

Ixempra

This page shows the latest Ixempra news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

Bayer fails to overturn Nexavar compulsory licence in India

drugs. There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down

Latest news

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... According to the Indian Express, Herceptin, Ixempra and Sprycel cost 50, 000 rupees (687), 70, 000-80, 000 rupees (961 to 1, 098) and 15, 000 rupees (206)

  • Eisai wins approval for breast cancer drug

    and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

  • Bristol-Myers signs cancer drug deal

    BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).

  • FDA approves BMS chemotherapy drug

    Ixempra was approved for use in women who have failed treatment on three other types of chemotherapy. ... Ixempra inhibits the protein tubulin, which stops cells growing and dividing by arresting the cell cycle.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics